SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

zoliflodacin

RDY·DR REDDYS LABORATORIES LTD
NEUTRAL
Drug Impact Rating3/10
Trial phase
Filed/PDUFA (NDA submitted, Priority Review granted, PDUFA date December 15, 2025 passed)
Time to market
Unknown, the PDUFA date of December 15, 2025 has passed with no recorded approval, suggesting the drug may have received a Complete Response Letter (CRL) or rejection. A resubmission timeline, if any, is not available in the data.
Why 3/10
The PDUFA date of December 15, 2025 has already passed with no recorded approval, the binary catalyst is resolved (appears negative). There is no scheduled next hard catalyst for this drug in the next ~12 months, so the impact score is low.
Actionable Insight NEUTRAL

The PDUFA catalyst for zoliflodacin (December 15, 2025) has already passed with what appears to have been a negative outcome (stock dropped ~3.4% on the day and continued declining). There is no upcoming hard binary catalyst for this drug in the next 12 months. For INVA investors, zoliflodacin is now a known-quantity overhang; the stock's thesis rests more on the core royalty portfolio and other pipeline assets.

Price Chart

Loading chart...

Executive Summary

Zoliflodacin is a novel oral antibiotic for uncomplicated gonorrhea developed by Innoviva, Inc. (INVA). The drug was granted FDA Priority Review and had a PDUFA date of December 15, 2025, but the outcome appears to have been negative, the stock dropped ~3.4% on the decision date and continued declining in subsequent weeks, with no FDA approval recorded in available data. The filing hint suggesting Dr. Reddy's (RDY) as the developer appears incorrect; all evidence points to Innoviva as the primary sponsor. With the PDUFA catalyst now resolved and no upcoming binary catalyst for this drug, zoliflodacin is no longer a near-term share-price driver for INVA.

How It Works

Zoliflodacin is a novel oral antibiotic that works by inhibiting bacterial DNA replication (a bacterial type II topoisomerase inhibitor). It is designed to treat uncomplicated gonorrhea, including drug-resistant strains, and is taken as a single oral dose, a significant convenience advantage over the current standard of care (injectable ceftriaxone plus oral azithromycin).

Trial Status

Innoviva submitted an NDA for zoliflodacin in mid-2025 (filed June 2025 per SEC-extracted data). The FDA granted Priority Review with a PDUFA target action date of December 15, 2025. The outcome of that PDUFA is not recorded as an approval in available data, and the stock declined on the decision date, suggesting a negative regulatory outcome.

The Two-Sided Case

▲ Bull Case4
Zoliflodacin is a novel, first-in-class oral antibiotic for gonorrhea (a bacterial topoisomerase inhibitor) that addresses growing antibiotic resistance, a major public health need.
The NDA was granted Priority Review by the FDA, indicating the agency viewed the drug as a significant therapeutic advance.
Analyst consensus on INVA is strongly bullish: 9 Buy/Strong Buy vs 2 Hold/Sell, with a mean price target of $35 (67.4% implied upside from ~$20.91).
Major institutional holders include BlackRock ($262M), Vanguard ($95M), and Renaissance Technologies ($91M) as of Q2 2026.
▼ Bear Case4
The PDUFA date of December 15, 2025 has passed with no recorded FDA approval, the stock dropped -3.44% on the decision date and continued falling to ~$19.30 in late December, strongly suggesting a Complete Response Letter (CRL) or rejection.
With no upcoming binary catalyst for this drug, there is no near-term positive event to re-rate the stock on this asset.
The drug treats uncomplicated gonorrhea, a large but generic-heavy market where pricing and adoption of a new branded antibiotic face headwinds.
Innoviva's core royalty revenue from GSK continues to decline (-4% YoY per Q1 2026 earnings), pressuring the top line.

Upcoming Catalysts

  • No upcoming hard catalyst for zoliflodacin identified in the next ~12 months. The PDUFA decision has passed.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

DR REDDYS LABORATORIES LTD 6-K RDY ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov